Enhertu wins two FDA breakthrough therapy designations

2023-08-31
Pharmaceutical Technology
临床结果ASCO会议上市批准突破性疗法临床2期
Enhertu wins two FDA breakthrough therapy designations
Preview
来源: Pharmaceutical Technology
Robert Barrie
Enhertu wins two FDA breakthrough therapy designations
Preview
来源: Pharmaceutical Technology
The ADC is already approved in different settings for patients with breast cancer, non-small cell lung cancer and gastroesophageal junction adenocarcinoma. Image credit: Shutterstock/Christoph Burgstedt.
The anti-cancer drug Enhertu is going from strength to strength in 2023 after the US Food and Drug Administration (FDA) granted two additional breakthrough therapy designations to the therapy.
Daiichi Sankyo and AstraZeneca are jointly developing and commercialising Enhertu (fam-trastuzumab deruxtecan-nxki), a human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC). With the latest news, the drug now has seven breakthrough designations to date.
Recommended Reports
Enhertu wins two FDA breakthrough therapy designations
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Docetaxel Albumin Bound in Solid Tumor GlobalData
Enhertu wins two FDA breakthrough therapy designations
Preview
来源: Pharmaceutical Technology
ReportsLOA and PTSR Model - Tgfbeta InhibitorTgfbeta Inhibitor in Solid Tumor GlobalData
View all
The ADC is approved in different settings for patients with breast cancer, non-small cell lung cancer and gastroesophageal junction adenocarcinoma. One of the two most recent designations is not limited to a particular type of cancer but is for the treatment of adult patients with unresectable or metastatic HER2-positive solid tumoursHER2-positive solid tumours that are not responding to treatment and who have no satisfactory alternative treatment options, signifying its pan-tumour potential.
In July 2023, the companies reported positive data from a Phase II trial, demonstrating clinically meaningful survival rates in patients across multiple HER2-expressing advanced solid tumoursHER2-expressing advanced solid tumours – including those found in biliary tract, bladder, cervical, endometrial, ovarian, and pancreatic cancers. The interim analysis of the DESTINY-PanTumor02, which was presented at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, showed Enhertu shrank tumours in 37.1% of patients in the trial.
Reacting to the results announced at the 2023 ASCO, former GlobalData senior oncology and haematology analyst Avigayil Chalk commented: “Tumour-agnostic approval would lead to increased sales for Enhertu, which already achieved blockbuster status in 2022, with global sales exceeding $1.6bn.
“GlobalData’s consensus forecast projects global sales for Enhertu to exceed $9.9bn by 2029, driven by increased uptake for already approved indications across markets and expansion into new indications.”
The second designation is for the treatment of patients with HER2-positive metastatic colorectal cancerHER2-positive metastatic colorectal cancer who have received two or more prior regimens.
AstraZeneca’s oncology R&D executive vice-president Susan Galbraith said: “This is an important step in bringing Enhertu to patients with a broad range of HER2 expressing solid tumours who currently face a poor prognosis.”
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。